391 related articles for article (PubMed ID: 3011900)
1. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
Wu MS; Biftu T; Doebber TW
J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
[TBL] [Abstract][Full Text] [Related]
4. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
9. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
10. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
[TBL] [Abstract][Full Text] [Related]
11. PAF and immune complex-induced injury.
Warren JS; Johnson KJ; Ward PA
J Lipid Mediat; 1990; 2 Suppl():S229-37. PubMed ID: 1966816
[TBL] [Abstract][Full Text] [Related]
12. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
Issekutz AC; Szpejda M
Lab Invest; 1986 Mar; 54(3):275-81. PubMed ID: 3951199
[TBL] [Abstract][Full Text] [Related]
13. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
Hwang SB; Lam MH; Hsu AH
Mol Pharmacol; 1989 Jan; 35(1):48-58. PubMed ID: 2536468
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
15. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1989 Jul; 250(1):293-300. PubMed ID: 2545861
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control.
Longphre M; Kleeberger SR
Am J Respir Cell Mol Biol; 1995 Nov; 13(5):586-94. PubMed ID: 7576695
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.
Perico N; Delaini F; Tagliaferri M; Abbate M; Cucchi M; Bertani T; Remuzzi G
Lab Invest; 1988 Feb; 58(2):163-71. PubMed ID: 3123798
[TBL] [Abstract][Full Text] [Related]
19. Intrapulmonary tumor necrosis factor triggers local platelet-activating factor production in rat immune complex alveolitis.
Warren JS; Barton PA; Mandel DM; Matrosic K
Lab Invest; 1990 Dec; 63(6):746-54. PubMed ID: 2255183
[TBL] [Abstract][Full Text] [Related]
20. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
